Which chemo works better for esophageal cancer? study compares two common drugs

NCT ID NCT07549269

Completed Knowledge-focused Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked back at 387 patients with esophageal cancer to compare two chemotherapy drugs, nab-paclitaxel and paclitaxel, given before surgery. The goal was to see which drug leads to better outcomes like complete cancer removal. The study is completed, but results are not yet published.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nab-paclitaxel and paclitaxel (chemotherapy drugs)
What this could lead to: If one drug proves better, it could guide doctors to choose the more effective chemotherapy for esophageal cancer patients before surgery.
What could go wrong: This is a retrospective study, not a controlled trial, so results may be less reliable. It also does not test a new treatment, just compares existing ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

West China Hospital

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.